Spinal cord injury therapy maker InVivo Therapeutics registers with the SEC for a $10 million funding round.
Spinal injury therapy maker InVivo Therapeutics Holdings Corp. (OTC:NVIV) is preparing a $10 million offering, SEC filings show.
Details haven't yet been made public regarding pricing, but the company expects to use the proceeds for research & development, working capital, capital expenditures and other general corporate purposes.
InVivo, co-founded in 2005 by industry celebrity Robert Langer, took itself public with a reverse merger last year.
The company filed its first investigational device exemption in July 2011 for a biopolymer scaffolding device intended to treat acute spinal cord injuries. InVivo anticipates approval for its IDE in 2012, at which point it can begin human clinical studies.
InVivo is a pre-revenue company, with losses totalling $12.7 million since inception, according to SEC filings.
The company has managed to pare losses and deficits in the last year, although its assets have diminished as well.
Will the $66 billion buyout of Allergan by Actavis suck some of the juice out of Orange County, Calif...
Johnson & Johnson wants a federal judge to make Boston Scientific cough up some $7.2 billion - 40...
Boston Scientific goes down in another product liability lawsuit over its pelvic mesh products.
What's a medical device company to do when Facebook and Twitter can spread word of its products...